Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis

Research output: Contribution to journalArticle

Abstract

Alemtuzumab is an anti-CD52 monoclonal antibody used for the treatment of lymphoproliferative disorders and relapsing-remitting multiple sclerosis. We report a 30-year-old woman with relapsing-remitting multiple sclerosis who developed a type 2 non-ST elevated myocardial infarction (NSTEMI) during her first alemtuzumab infusion cycle. While acute coronary syndrome has been described with alemtuzumab in the treatment of lymphoma, alemtuzumab-associated cardiac ischemia in multiple sclerosis is uncommon and can occur in patients without cardiovascular risk factors.

Original languageEnglish (US)
Pages (from-to)100-102
Number of pages3
JournalMultiple Sclerosis and Related Disorders
Volume34
DOIs
StatePublished - Sep 1 2019

Fingerprint

Relapsing-Remitting Multiple Sclerosis
Myocardial Infarction
Lymphoproliferative Disorders
Acute Coronary Syndrome
Multiple Sclerosis
Lymphoma
Ischemia
Monoclonal Antibodies
alemtuzumab
Therapeutics

Keywords

  • Acute coronary syndrome
  • Adverse events
  • Alemtuzumab
  • Multiple sclerosis

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

@article{e45cb31a3e7f4f82b936e646dc7366bd,
title = "Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis",
abstract = "Alemtuzumab is an anti-CD52 monoclonal antibody used for the treatment of lymphoproliferative disorders and relapsing-remitting multiple sclerosis. We report a 30-year-old woman with relapsing-remitting multiple sclerosis who developed a type 2 non-ST elevated myocardial infarction (NSTEMI) during her first alemtuzumab infusion cycle. While acute coronary syndrome has been described with alemtuzumab in the treatment of lymphoma, alemtuzumab-associated cardiac ischemia in multiple sclerosis is uncommon and can occur in patients without cardiovascular risk factors.",
keywords = "Acute coronary syndrome, Adverse events, Alemtuzumab, Multiple sclerosis",
author = "Romba, {Meghan C.} and Scott Newsome and McArthur, {Justin Charles}",
year = "2019",
month = "9",
day = "1",
doi = "10.1016/j.msard.2019.06.022",
language = "English (US)",
volume = "34",
pages = "100--102",
journal = "Multiple Sclerosis and Related Disorders",
issn = "2211-0348",
publisher = "Elsevier",

}

TY - JOUR

T1 - Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis

AU - Romba, Meghan C.

AU - Newsome, Scott

AU - McArthur, Justin Charles

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Alemtuzumab is an anti-CD52 monoclonal antibody used for the treatment of lymphoproliferative disorders and relapsing-remitting multiple sclerosis. We report a 30-year-old woman with relapsing-remitting multiple sclerosis who developed a type 2 non-ST elevated myocardial infarction (NSTEMI) during her first alemtuzumab infusion cycle. While acute coronary syndrome has been described with alemtuzumab in the treatment of lymphoma, alemtuzumab-associated cardiac ischemia in multiple sclerosis is uncommon and can occur in patients without cardiovascular risk factors.

AB - Alemtuzumab is an anti-CD52 monoclonal antibody used for the treatment of lymphoproliferative disorders and relapsing-remitting multiple sclerosis. We report a 30-year-old woman with relapsing-remitting multiple sclerosis who developed a type 2 non-ST elevated myocardial infarction (NSTEMI) during her first alemtuzumab infusion cycle. While acute coronary syndrome has been described with alemtuzumab in the treatment of lymphoma, alemtuzumab-associated cardiac ischemia in multiple sclerosis is uncommon and can occur in patients without cardiovascular risk factors.

KW - Acute coronary syndrome

KW - Adverse events

KW - Alemtuzumab

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=85067811049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067811049&partnerID=8YFLogxK

U2 - 10.1016/j.msard.2019.06.022

DO - 10.1016/j.msard.2019.06.022

M3 - Article

C2 - 31252364

AN - SCOPUS:85067811049

VL - 34

SP - 100

EP - 102

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

SN - 2211-0348

ER -